Arteriovenous Fistula Clinical Trial
Official title:
Inflammatory Marker and Pre-existing Venous Fibrosis to Predict AVF Mal-maturation
End-stage renal disease patients needs a functional vascular access to receive hemodialysis and prolong their lives. Arteriovenous fistula (AVF) is priority consideration for hemodialysis, which is a connecting a superficial vein to a nearby artery and allowing this vein to enlarge and increase in internal diameter under arterial circulation. Unfortunately, 30-50% of fistulae fail to mature. Vascular calcification and stenosis were considered for early failure. The perivascular fat of artery can be predicted successful AVF maturation. However, Few previous studies have compared AVF maturation between perivascular the fat of cephalic vein or removal during the AVF surgery. This study evaluated whether the effect of AVF inflammation and preexisting vascular fibrosis is associated to perivascular the fat of cephalic vein. Investigators will also verify inflammation by analysis of blood and tissue samples, the association of pre-existing fibrosis, and the clinical correlation with AVF early failure. This study will enroll patients with chronic kidney disease stage 5 and stage 6 who will need maintenance-hemodialysis (HD) from Nov 2021 to Dec 2022. Investigators will use the preoperative ultrasound assessment tool to confirm the feasibility of the arm vessels for the creation of a native AVF. As a prospective randomized controlled trial of perivascular fat preservation or removal during the AVF surgery, a study assistant will help the randomization and explain the informed consent to the patient . The subjects are randomly split into two groups: the experimental group will have the perivascular fat of the target cephalic vein preserved the control group will have the fat removed before the AVF anastomosis. The survey will enroll 100 adult patients and categorize them into groups according to each AVF maturation, JAS, or FTM (see definition below) by 3 - 12 after the surgery.
The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis, which is surgically created but connecting a superficial vein to nearby artery and allowing this vein to enlarge and increase in internal diameter under arterial circulation. Successful fistula maturation depends on dilatation and remodeling of the artery and vein, but the stiff and thickened vessels of end-stage renal diseases (ESRD) patients may respond poorly to signals that promote these adaptations. About 20 - 40% of AVFs maturation fails and no effective treatment to prevent AVF maturation failure. Paulson WD summarized four points for maturation failure. Surgical skill; preexisting vascular disease; Upstream events; and Downstream events. Upstream events are the mechanisms that initially cause injury to the endothelium (surgical trauma, hemodynamic shear stress, vessel wall injury caused by needle punctures, etc.). Downstream events are the responses to endothelial injury (leukocyte adhesion, migration of smooth muscle cells from the media to the intimal layer, smooth muscle proliferation, etc.). However, upstream and downstream events are important steps in maturation failure, preexisting vascular disease should not be neglected as it sets the stage for what follows. Medial collagen fibers are organized into lamellar units and oriented circumferentially with crimps in healthy blood vessels. However, higher medial collagen content maybe stiffer and limited ability to dilate. Recently, researches have shows preexisting fibrosis condition in veins was associated with maturation. Inflammation for AVF setting can be divided into two parts: local and systemic inflammation. For local inflammation had been indicated caused by the trauma of fistula creation and local hypoxia; For systemic inflammation, which occurs because of uremia present in CKD patients. Recent study have suggested AVF failure was linked to inflammation. The perivascular fat of artery can be predicted successful AVF maturation. Lipectomy of cephalic vein is a routine method during hemodialysis arteriovenous fistula creation[9]. However, Few previous studies have compared AVF maturation between perivascular the fat of cephalic vein or removal during the AVF surgery. Specific aims Successful fistula maturation depends upon dilatation and remodeling of the artery and vein, but the stiff and thickened vessels of ESRD patients may respond poorly to signals that promote these adaptations. Although our preliminary data showed that preexisting vascular fibrosis increased in AVFs failure. But the finding still needs more verifications. In this study, Investigators will focus on the finding of molecular marks to be related to AVFs maturation or failure. The study include the following sections: 1. Whether vascular fibrosis exists in AVF patients and its association with maturation failure. 2. Whether vascular fibrosis is associated with inflammation. 3. Examine the cytokines expression of neutrophil in blood. 4. Whether the perivascular fat of cephalic vein is associated with AVF failure Aim 1. Whether vascular fibrosis exists in AVF patients and its association with maturation failure. Investigators will observe vascular fibrosis by histopathology and western blot. First of all, the subjects are those adult uremic patients who will undergo an AVF creation. The survey will enroll the patients with chronic kidney disease (CKD) stage 5 (CKD-5) and stage 6 (CKD-6) who will need maintenance-hemodialysis (HD). Investigators will use the preoperative ultrasound assessment tool to confirm the feasibility of the arm vessels for the creation of a native AVF. As a prospective randomized controlled trial of perivascular fat preservation or removal during the AVF surgery, a study assistant will help the randomization and explain the informed consent to the patient. The subjects are randomly split into two groups: the experimental group will have the perivascular fat of the target cephalic vein preserved the control group will have the fat removed before the AVF anastomosis. The surgeon will harvest the distal vein stump and 1 cm of subcutaneous fat for at least 1.5-cm in length during an AVF creation, at the same time will get a 10-cc plasma sample. The survey will enroll 100 adult patients and categorize them into groups according to each AVF maturation, JAS, or FTM (see definition below) by 3 - 12 after the surgery. Preoperative vascular ultrasound assessment. All patients will have clinical and ultrasound exam to assess the suitability of surgery, The patient will be excluded If their vessels and/or clinical condition are not suitable used to hemodialysis. A hemodialysis arteriovenous fistula (HDAVF) maturity score based on the following three objective ultrasonic measurements. Give a summary score range from 0 to 9 points. Higher scores indicating more mature. Ultrasound testing parameters are defined as follows: 1. Measuring the arm artery diameter and total blood flow. The brachial artery is defined as measured from the proximal 4 (+/- 2,2 to 6) cms within the curved line of the elbow, Investigators will measure the vascular diameter and estimate total forearm blood flow. 2. Radial artery scan of the forearm is defined as the diameter of the radial artery scanned from the start of the antecubital to the wrist.line. Notedly, Investigators also confirm its diameter> = 2.0 mm and identify no obvious stenosis of the antecubital to the wrist.line. Notedly, Investigators also confirm its diameter> = 2.0 mm and identify no obvious stenosis. 3. Measure the non-augmented diameter of the cephalic vein. The midpoint of it is defined as the middle between the elbow line and the wrist line, Which is around 10 (+/- 2, 8 ~ 12) cms distal to the elbow. 4. Measure the augmented diameter of the cephalic vein. Pressure is applied to the upper arm with tourniquet cuff to 100-mm-Hg temporarily and which provides moderate resistance, wait 30 seconds, then investigators measure the cephalic vein where has been defined above. Accordingly, the definition of venous compliance is defined as the degree of venous dilatation of the cephalic vein before and after augmentation. Furthermore, the compliance of vein is defined as the percentage of augmented / non-augmented cross-section area of the vein. 5. Investigators will confirm the whole segment of cephalic vein is to be> 2.0 mm in diameter and identify no significant stenosis. Definition of clinical success: It is defined as the target HDAVF can be used by two needles and complete the HD session for at least ⅔ of prescribing sessions in a month. A minimum criterion of a run is at an average blood flow rate of 300 ml/min in a 3.5-hour HD session to achieve a target sp-Kt/V of 1.2.14 In which a successful HD session is defined as completion of HD with a dialysis flow rate is more than 200 ml/min, and a session duration of 4 hours or more. Definition of success by ultrasound parameters: the survey proposes an objective ultrasound scoring system and considers a total score of four or more as AVF maturation. For histology analysis, samples were paraffin-embedded and sectioned. H&E (hematoxylin and eosin) are common stains used in histology. The hematoxylin stains cell nuclei is blue, and eosin stains the extracellular matrix and cytoplasm presents pink. The Movat pentachrome staining can be demonstrated that collagen, elastin, muscle mucin and fibrin in tissue sections. Investigators use Sirius-red staining to observe the collagen I and III fibers in tissue sections. In order to detect calcium deposits, Investigators use Alizan red staining. The Masson's trichrome will be used to stain. In the trichrome stain, smooth muscle appears red, and collagen appears blue. For western blot assay, collagen, α-SMA, TIMP-1, and TIMP2 expression will increase in vascular fibrosis. Hence, investigators will detect expression of collagen, α-SMA, MMP-9, MMP2, TIMP-1, TIMP2 in AVF maturation and failure tissue. Tissues were homogenized and lysed. Protein concentration for each tissue extract was determined using a BCA protein assay according to the instructions of the supplier (Pierce Chemical Co., Rockford, Illinois, USA). Fifty microgram of tissue lysates protein per lane were separated by SDS-PAGE under reducing conditions and blotted onto PVDF membranes (Millipore Corp., Bedford, Massachusetts, USA). Membranes were blocked in 5% defatted dry milk/ PBS/0.1% Tween-20 (PBST) and were then incubated with the primary antibody for 1 hour. Blots were washed 4 times PBST, and the secondary peroxidase-conjugated antibody (Jackson ImmunoResearch Labora-tories Inc., West Grove, Pennsylvania, USA) was added (1:10,000) for another hour. Finally, membranes were washed in PBST, and detection of the antigen was carried out using the enhanced chemiluminescence detection method according to the manufacturer's recommendations Aim 2. Whether vascular fibrosis is associated with inflammation. Inflammation in the setting of AVF was involved locally and systemically. Local inflammation caused by trauma of fistula creation and local hypoxia. So, investigators will measure the IL8, IL1b, IL6, IL10, TNF, IL12p70, CCL5(RANTES), CXCL9 (MIG), CCL2 (MCP1), IP10 and compare expression between AVF maturation and failure tissue by QPCR and Multiplex ELISA. Beside, systemic inflammation occurs because of uremia that is present in chronic kidney diseases. Also, investigators will detect expression of IL8, IL1b, IL6, IL10, TNF, IL12p70, CCL5(RANTES), CXCL9 (MIG), CCL2 (MCP1), IP10 and compare expression between AVF maturation and failure serum by CBA assay. For QPCR assay, RNA was extracted from vein tissue by the TRIzol protocol (Life Technologies, Invitrogen). RNA concentrations were quantified by Nanodrop. The purity of the total RNA extracted was determined as the 260/280 nm ratio and the integrity was checked. QPCR was performed by the TaqMan system. For ELISA assay, tissues were lysed in PBS buffer and using commercial ELISA kits (R&D) according to the manufacturer's protocol. The lysates were normalized to the total protein content determined using a commercial BCA protein assay kit. For Cytokine Bead Array (CBA) assay, the Human Inflammatory Cytokines CBA Kit (BD Biosciences, San Jose, CA) was used, which measures all of the above cytokines except GM-CSF, IL-2, and IFN-γ; data were acquired on a BDTM FACS caliber flow cytometer. Both assays were performed according to the manufacturer's instructions except for the use of modified calibration curves as described below. All standards and samples were measured in duplicate. Aim 3. Examine the cytokines expression profile of neutrophilic in blood. To perform this, investigators will examine the peripheral blood neutrophil population by flow cytometry stain with CD11b+/CD66b/CD34/CD45. Next to determine the percentage of neutrophils expressing target cytokines in peripheral blood. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05302505 -
Simulation-based Training for Nurses and Arteriovenous Fistula Puncture in Chronic Hemodialysis Patients
|
N/A | |
Terminated |
NCT01642459 -
The Outcomes of Arteriovenous Fistula Cannulated From Different Direction.
|
N/A | |
Recruiting |
NCT04017806 -
Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation
|
||
Terminated |
NCT03668002 -
Trial of Fistula Versus Graft in Elderly Patients
|
N/A | |
Completed |
NCT06199609 -
Changes in Cardiac Structure and Function After Establishment of Autologous Arteriovenous Fistula
|
||
Recruiting |
NCT04034433 -
Exercise Program for Arteriovenous Fistula Maturation
|
N/A | |
Active, not recruiting |
NCT04629118 -
Intervention With Selution SLR™ Agent Balloon for Endovascular Latent Limus Therapy for Failing AV Fistulas (ISABELLA) Trial
|
||
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Recruiting |
NCT05616104 -
FLEX FIRST Registry Research Protocol
|
||
Recruiting |
NCT03886116 -
Effect of Pre-operative Forearm Exercises on Arterial Venous Fistula Maturation and Blood Flow
|
N/A | |
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Completed |
NCT01863914 -
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
|
Phase 2 | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A | |
Recruiting |
NCT04543539 -
IN.PACT™ AV Access Post-Approval Study (PAS002)
|
||
Completed |
NCT05326321 -
Effect of Virtual Reality Glasses in The Arteriovenous Fistule Cannulation Processon Paın and Patient Satisfaction
|
N/A | |
Recruiting |
NCT03741985 -
Effect of Dumbbell Exercise on Arteriovenous Fistula in Patients With Hemodialysis
|
N/A | |
Terminated |
NCT03566927 -
FLEX®-DCB Dialysis ACCESS Stenosis Study
|
N/A | |
Not yet recruiting |
NCT04393688 -
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV Fistula
|
N/A | |
Recruiting |
NCT02447796 -
Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery
|
Phase 4 | |
Terminated |
NCT01321866 -
Cutting Balloon Versus Non-cutting Balloon for the Treatment of Venous Stenosis in the Fistulas of Hemodialyzed Patients
|
N/A |